NEW YORK, NY / ACCESSWIRE / September 1, 2016 / MP Advisors, a consultancy firm with an exclusive focus on Pharmaceuticals / Biotechnology sectors in the US, Europe, India, Japan and Russia, today announces the release of a new research report on Cellceutix Corporation (OTCQB: CTIX). Cellceutix is a clinical stage biopharmaceutical company based in Beverly, Massachusetts developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications.

The 32-page report provides an in-depth analysis of the Cellceutix pipeline of drugs in development, intellectual property, key drivers, upcoming milestones and a sum of parts valuation. The report takes a detailed look at development and clinical research of Brilacidin and its multiple target indications (e.g. infectious disease, palliative care, gastrointestinal disease, dermal conditions); Prurisol as a new oral treatment for plaque psoriasis; Kevetrin for solid tumors; and preclinical research being conducted by Cellceutix. Our comprehensive analysis includes a view of the competitive landscape of drugs marketed and in development by others to deliver an unbiased outlook as to the current and future market opportunity and fair value of the Cellceutix pipeline.

More succinctly, the report covers:

  • Executive Summary
    • Key Drivers
    • Upcoming Milestones
    • Sum of Parts Valuation
  • Key Drivers
    • Brilacidin ? A Multifaceted Asset
      • Brilacidin- Anti-Infective / Infectious Disease
        • Mechanism of Action
        • Anti-infective Opportunity
        • Brilacidin's Edge Over Competitors in Infection
        • Clinical Data of Brilacidin in ABSSSI ? The Antibiotic Gateway
        • Competitive Landscape in ABSSSI
        • Market Opportunity beyond ABSSSI
      • Brilacidin in other Therapy Areas
        • Palliative Cancer: Oral Mucositis (OM)
          • Oral Mucositis
          • Brilacidin's Edge over Approved and Other Competitor in Development
          • Clinical Development Landscape in OM
          • Market Opportunity
        • Gastrointestinal diseases/Inflammation: Inflammatory bowel diseases ? Ulcerative proctitis/proctosigmoiditis
          • Market Opportunity
          • Clinical Development and Data
        • Dermal Infection: Hidradenitis suppurativa (HS), Acne
    • Prurisol ? Promising Oral drug for Plaque Psoriasis
      • Market opportunity
      • Prurisol ? Clinical Development and Data in Psoriasis
      • Competitive Landscape ? Oral Drugs for Psoriasis
      • Similarity between Prurisol and Apremilast/Otezla
      • Safety concerns in the approval of Oral RA drugs in Psoriasis
    • Kevetrin: Solid Tumors ? Ovarian Cancer
      • Market Opportunity in Ovarian Cancer
      • Targeted Therapy ? PARP Inhibitors and Competitive Landscape
      • Clinical Development and Data
    • Other Preclinical Programs
  • Regulatory
  • Management
  • Intellectual Property
  • Key Assumptions for Valuation

Interested parties are encouraged to view the complete report at: www.mpadvisor.com. The report will be available for at no cost for a period of 30 (thirty) days.

About MP Advisors

MP Advisors is a Consultancy firm with an exclusive focus on Pharmaceuticals / Biotechnology sectors in the US, Europe, India, Japan and Russia. Today it has a highly motivated, qualified team of PhD's, MBA's and Pharmacist who apply their domain knowledge to develop proprietary data bases, understand dynamic regulatory laws across geographies, track and analyze latest trends in drug development, clinical trials and specific diseases.

MP Advisors has insightful information on more than 200 pharma and Biotech companies around the globe as well as publishes reports on Key Opinion Leaders (Physician's view) assessment, therapy class review of several classes (e.g. Oral anticoagulants, Hepatitis C, Obesity, Novel Drug Delivery systems, Biosimilars etc.), India and Japan generic opportunities and Paragraph IV Opportunities.

SOURCE: MP Advisors